Exact Therapeutics Announces Clinical Trial Update
OSLO/LONDON, 08 March 2022
EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage
precision health company utilizing Acoustic Cluster Therapy (ACT®) across
multiple therapeutic areas, today provides an update regarding the phase I
ACTIVATE study.
As reported in Q4 2021, EXACT-Tx filed a protocol amendment regarding its
ACTIVATE phase I clinical trial with the United Kingdom Medicines and Healthcare
products Regulatory Agency (MHRA). This week the MHRA issued a response to
EXACT-Tx requiring an additional submission and approval of documentation
regarding the protocol amendment. The Company expects that meeting this
requirement which is specifically focused on the Ultrasound system used in
combination with PS101, from the regulator will impact the timing of additional
patient recruitment. 

So far, there have been seven patients enrolled in the study with five patients'
data evaluable to date for dose limiting toxicity. A number of valuable and
encouraging insights have been gained from this first cohort of treated
patients.  
ENDS
For more information, please contact:

Dominic Moreland
EXACT Therapeutics 
Email: Dominic@exact-tx.com

Optimum Strategic Communications
Eva Haas / Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®).  ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.